Clinical Trial

ExCrossV Multi Site Trial for Vascularized High Risk Keratoplasty

Study acronym: ExCrossV
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The main objective of this study is to determine the safety of Ex Vivo Cross Linking (CXL) of donor corneal tissue in participants who have undergone high-risk penetrating keratoplasty.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-12-20; most recent amendment 2026-04-17.
Status change: Not Yet Recruiting → Recruiting 2025-07-17
Trial Details
NCT Number NCT06753916
Lead Sponsor Massachusetts Eye and Ear Infirmary
Conditions Corneal Transplant Failure
Enrollment 96 participants
Start Date 2025-04-01
Primary Completion 2028-01-01 (estimated)
Study Completion 2031-01-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-21